✨ Free AI Report
CohBar, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview CohBar, Inc.
Research Preview

CohBar, Inc.: Business Overview, Financials & Competitive Analysis

CohBar, Inc. was a clinical-stage biotechnology company headquartered in Menlo Park, California that developed mitochondria-based therapeutics targeting chronic and age-related diseases. The company pioneered the expl...

Analyst-debate audio for CohBar, Inc.

AskCyborg analysts argue the bull and bear cases for CohBar, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
CohBar, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
2/ 10Challenged

Cyborg Score thesis

CohBar's mitochondrial therapeutic platform was discontinued post-merger, making it a defunct entity of primarily historical...

Read the full analyst-debate transcript →
Industry Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest CohBar, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

CohBar, Inc. Overview

Pro stress-test →

CohBar, Inc. was a clinical-stage biotechnology company headquartered in Menlo Park, California that developed mitochondria-based therapeutics targeting chronic and age-related diseases. The company pioneered the exploration of mitochondrial genome-encoded peptides as a novel therapeutic approach, discovering over 100 mitochondrial-derived peptides and generating 1,000+ analogs. The company is no longer operating as of 2023 following a merger with Morphogenesis.

Strategic Profile

Pro stress-test →

CohBar held a differentiated position as the first company to mine the mitochondrial genome for therapeutically relevant peptides, establishing a robust IP portfolio. The company's lead candidate, CB4211, was in Phase 1b clinical trials for NASH and obesity. The merger with Morphogenesis shifted focus from mitochondrial therapeutics to personalized cancer vaccines and tumor microenvironment modulators under the new TuHURA Biosciences entity.

Competitive Landscape

Pro stress-test →

In its pre-merger period, CohBar competed in the mitochondrial therapeutics and age-related disease treatment space against broader biotech companies developing metabolic and liver disease therapies. Post-merger, the combined entity focused on competing in the personalized cancer vaccine market against established immunotherapy platforms.

Industry Context

CohBar, Inc. operates in Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger).

Key facts

Founded: 2007 · Headquarters: Menlo Park, US · Employees: 11 · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on CohBar, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when CohBar, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ExelixisOncology therapeutics→Selecta BiosciencesCell and gene therapy→Forty Seven IncImmuno-oncology→

Compare CohBar, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CohBar, Inc. operates in Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Mitochondrial Therapeutics / Immuno-Oncology (post-merger) research →
NEW · MCP server

Ask your AI assistant about CohBar, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CohBar, Inc. and its top competitor on Cyborg Score”
“What did CohBar, Inc. do this quarter?”
“Is CohBar, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does CohBar, Inc. do?+
CohBar, Inc. was a clinical-stage biotechnology company headquartered in Menlo Park, California that developed mitochondria-based therapeutics targeting chronic and age-related diseases. The company pioneered the expl...
What is CohBar, Inc.'s Cyborg Score?+
CohBar, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CohBar, Inc.'s main competitors?+
Named competitors include Exelixis, Selecta Biosciences, Forty Seven Inc. The full competitive landscape is in the AskCyborg report.
How can I get the full CohBar, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CohBar, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CohBar, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Mitochondrial Therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Exelixis, Inc.